Heparin dosing in patients undergoing coronary intervention.
Unfractionated heparin remains an essential component of the antithrombotic regimen in patients undergoing coronary intervention, although the timing, dosing, and duration of heparin therapy have evolved over the past several years. Complications associated with heparin use include bleeding events, which occur in 3.9-16.4% of patients receiving conventional heparin. Less commonly, clinically significant thrombocytopenia develops, related to the duration of heparin administration. In patients undergoing coronary intervention who do not receive platelet glycoprotein (GP) IIb/IIIa inhibitors, sufficient heparin should be given to achieve an activated clotting time (ACT) of 250-300 seconds with the HemoTec device and 300-350 seconds with the Hemochron device. There is a general trend to use lower, weight-adjusted heparin dosing (70-100 units/kg) to avoid excessive levels of anticoagulation, with additional heparin boluses to achieve a therapeutic ACT level. When GP IIb/IIIa inhibitors are used, weight-adjusted heparin dosing can be decreased to 70 units/kg to achieve a target ACT of 200 seconds with either the HemoTec or Hemochron device. After uncomplicated coronary intervention, there appears to be little value associated with continued heparin therapy, and the risk of bleeding complications clearly increases with longer durations and higher levels of anticoagulation after coronary intervention.
Popma
J J
JJ
Department of Internal Medicine, the Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Prpic
R
R
Lansky
A J
AJ
Piana
R
R
D000925:Anticoagulants / Q000627:therapeutic use*; D003327:Coronary Disease / Q000628:therapy*; D016903:Drug Monitoring / Q000379:methods*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced; D014914:Whole Blood Coagulation Time
D000925:Anticoagulants; D006493:Heparin